Stoke Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Stoke Therapeutics, Inc. (STOK) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 529.86 thousand shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-03
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 529.86K shares, a 30.03% increase year-over-year.
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 1.34M shares, a 31.54% decline year-over-year.
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 1.13M shares.
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 809.30K shares, a 10.97% increase year-over-year.
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 4.31M shares, a 54.04% increase from fiscal 2024.
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.80M shares, a 74.94% increase from fiscal 2023.
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.60M shares, a 53.77% decline from fiscal 2022.
- Stoke Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 3.46M shares, a 163.70% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 529.86K shares 10-Q · filed 2026-08-03 | 1.87M shares derived: sum of 2 quarters · filed 2026-08-03 | 3.00M shares derived: sum of 3 quarters · filed 2026-08-03 | 3.81M shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 1.34M shares 10-Q · filed 2026-05-07 | 2.47M shares derived: sum of 2 quarters · filed 2026-05-07 | 3.28M shares derived: sum of 3 quarters · filed 2026-05-07 | 3.69M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 1.13M shares derived: 10-K 12 month − 3 quarters · filed 2026-03-16 | 1.94M shares derived: sum of 2 quarters · filed 2026-03-16 | 2.35M shares derived: sum of 3 quarters · filed 2026-03-16 | 4.31M shares 10-K · filed 2026-03-16 |
| 2025-09-30 | 809.30K shares 10-Q · filed 2025-11-04 | 1.22M shares derived: sum of 2 quarters · filed 2025-11-04 | 3.18M shares derived: sum of 3 quarters · filed 2025-11-04 | |
| 2025-06-30 | 407.48K shares 10-Q · filed 2025-08-12 | 2.37M shares derived: sum of 2 quarters · filed 2025-08-12 | ||
| 2025-03-31 | 1.96M shares 10-Q · filed 2025-05-13 | |||
| 2024-12-31 | 2.80M shares 10-K · filed 2026-03-16 | |||
| 2024-09-30 | 729.30K shares 10-Q · filed 2024-11-05 | 1.63M shares derived: sum of 2 quarters · filed 2024-11-05 | 2.73M shares derived: sum of 3 quarters · filed 2024-11-05 | |
| 2024-06-30 | 897.71K shares 10-Q · filed 2024-08-07 | 2.00M shares derived: sum of 2 quarters · filed 2024-08-07 | ||
| 2024-03-31 | 1.10M shares 10-Q · filed 2024-05-06 | |||
| 2023-12-31 | 1.60M shares 10-K · filed 2025-03-18 | |||
| 2023-09-30 | 96.34K shares 10-Q · filed 2023-11-07 | 377.93K shares derived: sum of 2 quarters · filed 2023-11-07 | 1.57M shares derived: sum of 3 quarters · filed 2023-11-07 | |
| 2023-06-30 | 281.59K shares 10-Q · filed 2023-08-07 | 1.47M shares derived: sum of 2 quarters · filed 2023-08-07 | ||
| 2023-03-31 | 1.19M shares 10-Q · filed 2023-05-04 | |||
| 2022-12-31 | 3.46M shares 10-K · filed 2024-03-25 | |||
| 2022-09-30 | 79.40K shares 10-Q · filed 2022-11-14 | 439.80K shares derived: sum of 2 quarters · filed 2022-11-14 | 2.50M shares derived: sum of 3 quarters · filed 2022-11-14 | 2.56M shares derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-06-30 | 360.40K shares 10-Q · filed 2022-08-08 | 2.42M shares derived: sum of 2 quarters · filed 2022-08-08 | 2.48M shares derived: sum of 3 quarters · filed 2023-03-06 | 2.55M shares derived: sum of 4 quarters · filed 2023-03-06 |
| 2022-03-31 | 2.06M shares 10-Q · filed 2022-05-10 | 2.12M shares derived: sum of 2 quarters · filed 2023-03-06 | 2.19M shares derived: sum of 3 quarters · filed 2023-03-06 | 2.35M shares derived: sum of 4 quarters · filed 2023-03-06 |
| 2021-12-31 | 60.95K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | 123.85K shares derived: sum of 2 quarters · filed 2023-03-06 | 289.35K shares derived: sum of 3 quarters · filed 2023-03-06 | 1.31M shares 10-K · filed 2023-03-06 |
| 2021-09-30 | 62.90K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 228.40K shares derived: sum of 2 quarters · filed 2021-11-08 | 1.25M shares 10-Q · filed 2021-11-08 | 1.34M shares derived: sum of 4 quarters · filed 2022-03-10 |
| 2021-06-30 | 165.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 1.19M shares 10-Q · filed 2021-08-10 | 1.28M shares derived: sum of 3 quarters · filed 2022-03-10 | 1.45M shares derived: sum of 4 quarters · filed 2022-03-10 |
| 2021-03-31 | 1.02M shares 10-Q · filed 2021-05-10 | 1.12M shares derived: sum of 2 quarters · filed 2022-03-10 | 1.28M shares derived: sum of 3 quarters · filed 2022-03-10 | 1.40M shares derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-12-31 | 92.88K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | 261.13K shares derived: sum of 2 quarters · filed 2022-03-10 | 376.12K shares derived: sum of 3 quarters · filed 2022-03-10 | 1.23M shares 10-K · filed 2022-03-10 |
| 2020-09-30 | 168.25K shares 10-Q · filed 2020-11-12 | 283.25K shares derived: sum of 2 quarters · filed 2020-11-12 | 1.14M shares 10-Q · filed 2020-11-12 | 1.30M shares derived: sum of 4 quarters · filed 2021-03-09 |
| 2020-06-30 | 114.99K shares 10-Q · filed 2020-08-10 | 970.40K shares derived: sum of 2 quarters · filed 2020-08-10 | 1.13M shares derived: sum of 3 quarters · filed 2021-03-09 | 1.30M shares derived: sum of 4 quarters · filed 2021-03-09 |
| 2020-03-31 | 855.41K shares 10-Q · filed 2020-05-15 | 1.02M shares derived: sum of 2 quarters · filed 2021-03-09 | 1.18M shares derived: sum of 3 quarters · filed 2021-03-09 | |
| 2019-12-31 | 161.10K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | 328.37K shares derived: sum of 2 quarters · filed 2021-03-09 | 1.23M shares 10-K · filed 2021-03-09 | |
| 2019-09-30 | 167.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | 1.07M shares 10-Q · filed 2019-11-12 | ||
| 2019-06-30 | 906.20K shares 10-Q · filed 2019-08-14 | |||
| 2018-12-31 | 2.97M shares 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |